Skip to main content

Table 3 Unadjusted Outcomes

From: Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study

  Inappropriate (n = 80) Appropriate (n = 10) P value*
ICU LOS (days)    
   Mean ± SD 10.8 ± 10.8 9.1 ± 10.1  
   Median (IQR 25, 75) 8 (4, 14) 4 (2, 14) 0.371
Hospital LOS (days)    
   Mean ± SD 24.4 ± 17.5 10.7 ± 9.4  
   Median (IQR 25, 75) 21 (13, 28) 8 (3, 16) 0.002
ICU cost ($)    
   Mean ± SD $13,448 ± $14,872 $12,801 ± $14,324  
   Median (IQR 25, 75) $10,249 ($4,290, $18,757) $5,545 ($2,750, $19,250) 0.559
Hospital cost ($)    
   Mean ± SD $66,584 ± $49,120 $33,526 ± $27,244  
   Median (IQR 25, 75) $52,437 ($35,977, $81,233) $26,916 ($11,388, $46,454) 0.006
Hospital LOS (days) following onset of CBSI    
   Mean ± SD 18.4 ± 17.0 10.7 ± 9.4  
   Median (IQR 25, 75) 13 (8, 22) 8 (3, 16) 0.062
Hospital mortality 23 (28.8%) 0 0.059
  1. *Derived using Mann Whitney U test for continuous variables and Fisher's exact test for categorical variable